Our findings not only contribute to the molecular oncology of CRC but also hold significant potential for the development of personalized treatment strategies, emphasizing the integral role of RT in the comprehensive management of BRAF-mutant CRC. This evidence concerns the gene BRAF and colorectal carcinoma.